在子宫内膜癌的精密内分泌疗法:它的时间终于来了吗?
1Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
概括
对于子宫内膜癌的内分泌疗法 (ET) 正在获得吸引力. 结合ET与循环林依赖性激酶4/6抑制剂,有望改善患者的治疗结果,克服治疗耐药性.
科学领域:
- 妇科瘤学 妇科瘤学
- 内分泌学 在内分泌学.
- 癌症治疗方法 癌症治疗方法
背景情况:
- 内分泌疗法 (ET) 从历史上来看,在子宫内膜癌管理中未得到充分利用.
- 最近的进展表明,ET和循环素依赖性激酶4/6 (CDK4/6) 抑制剂之间存在潜在的协同作用.
- 了解和克服抵抗机制对于推进ET疗效至关重要.
研究的目的:
- 审查目前的环境和精确内分泌治疗子宫内膜癌的未来机会.
- 探索克服对内分泌疗法耐药性的策略.
- 为了补充现有的CDK4/6抑制剂与ET结合的研究.
主要方法:
- 审查新出现的数据和科学文献.
- 评论最近在子宫内膜癌治疗方面的发现.
- 分析潜在的治疗组合和抵抗机制.
主要成果:
- 结合内分泌疗法和CDK4/6抑制剂在临床前和早期临床研究中显示出更好的结果.
- 通过纳入有针对性的代理人和个性化的方法来完善ET的机会存在.
- 识别和解决耐药性途径是提高治疗耐久性的关键.
结论:
- 精密内分泌疗法,可能与CDK4/6抑制剂相结合,代表了治疗子宫内膜癌的有前途途途.
- 进一步的研究是有必要的,以优化组合策略和管理ET抵抗.
- 个性化方法对于最大限度地提高内分泌治疗在子宫内膜癌的益处至关重要.
更多相关视频
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
11.2K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
119
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
119
